Lonza Group

LONN.SW Large Cap

Healthcare · Diagnostics & Research

Updated: Apr 5, 2026, 17:43 UTC

CHF 512.20

-0.35% today

52W: CHF 454.60 – CHF 605.20

52W Low: CHF 454.60 Position: 38.2% 52W High: CHF 605.20

🔗 Compare Brokers

Key Metrics

P/E Ratio

39.37x

Price-to-Earnings

Forward P/E

23.57x

Forward Price/Earnings

P/S Ratio

5.5x

Price-to-Sales

EV/EBITDA

18.62x

Enterprise Value/EBITDA

Div. Yield

98%

Annual dividend yield

Market Cap

$35.9B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

-4.21%

Net profit margin

ROE

10.48%

Return on Equity

Beta

0.89

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

167,600

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

23 analysts

Avg. Price Target

CHF 675.78

+31.94% upside

Target Range

CHF 550.00 – CHF 815.00

About the Company

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, develo

Sector: Healthcare Industry: Diagnostics & Research Country: Switzerland Employees: 19,771 Exchange: EBS